Eltrombopag as bridging therapy to haematopoietic stem cell transplant in severe or very severe aplastic anaemia during the COVID19 pandemic (in adults): Rapid Policy Statement

This document sets out the recommendations for the use of eltrombopag as bridging therapy to haematopoietic stem cell transplant in patients with severe or very severe aplastic anaemia during the COVID-19 pandemic. Specific inclusion, exclusion and stopping criteria apply.

NHS England